Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Verastem, Inc. Chief Financial Officer Form 4 filing reports a small, routine sale of company stock tied to equity compensation. On January 12, 2026, the CFO, Daniel Calkins, sold 5,039 shares of Verastem common stock at $7.16 per share. According to the footnote, this sale was made to satisfy statutory withholding tax requirements in connection with the vesting of restricted stock units, rather than as a discretionary sale of shares.
Following this transaction, the reporting person beneficially owned 104,719 shares of Verastem common stock, held directly. The filing is made by a single reporting person in the capacity of Chief Financial Officer and reflects standard administration of equity awards.
Verastem, Inc. filed a current report to inform investors that it has posted an updated corporate presentation on its website. The updated presentation, dated January 8, 2026, is also included as Exhibit 99.1.
This type of disclosure is meant to provide the market with the same information that the company is sharing in its investor materials, helping ensure all investors have equal access to the updated corporate overview and strategy details.
Verastem, Inc. reported an insider equity award for Michael Kauffman, who serves as both a director and President of Development. On January 6, 2026, he received a stock option covering 200,000 shares of Verastem common stock with an exercise price of $6.88 per share, held directly.
The option vests over three years: 33.33% of the shares vest on the first anniversary of the January 6, 2026 grant date, and an additional 8.33% vest at the end of each three‑month period thereafter until the third anniversary. Vesting requires that Kauffman continue to serve as an employee or other service provider to Verastem on each vesting date.
Verastem, Inc. director reports small share sale for tax withholding
A Verastem, Inc. director reported selling 592 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the director beneficially owns 101,147 shares of Verastem common stock in direct form.
The filing explains that the shares sold were used to satisfy statutory tax withholding obligations that arose when restricted stock units vested, meaning the transaction relates to equity compensation rather than a discretionary open‑market sale of the director’s investment position.
Verastem, Inc. reported that its President and CEO, who also serves as a director, carried out a small sale of company stock. On 12/16/2025, the executive sold 393 shares of Verastem common stock at a price of $9.14 per share. According to the filing, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, meaning it was tied to equity compensation rather than an open-market portfolio decision. After this transaction, the executive still beneficially owns 410,425 shares of Verastem common stock, held directly.
Verastem, Inc. director reports small stock sale for tax withholding
A director of Verastem, Inc. (VSTM) reported the sale of 283 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the reporting person beneficially owns 41,678 shares of Verastem common stock in direct ownership. According to the footnote, the sale was made to cover statutory tax withholding obligations related to the vesting of restricted stock units, rather than as a discretionary open-market sale.
Verastem, Inc. reported that its President and CEO, who is also a director, sold common stock in two transactions under a Rule 10b5-1 trading plan.
On December 10, 2025, the insider sold 2,000 shares of Verastem common stock at $10.07 per share, and on December 11, 2025, sold another 2,000 shares at $10.00 per share. Following these sales, the insider directly beneficially owned 410,818 shares of Verastem common stock.
Verastem, Inc. (VSTM) director reports option exercise and share sale. On 11/21/2025, the reporting person exercised stock options for 6,250 shares of common stock at an exercise price of $3.27 per share and sold 6,250 common shares at a weighted average price of $10.00 per share under a Rule 10b5-1 trading plan. Following these transactions, the reporting person held 2,083 shares of Verastem common stock directly and 6,250 stock options directly.
Verastem, Inc. (VSTM) director reported an open-market sale of common stock. On 11/21/2025, the reporting person sold 8,550 shares of Verastem common stock at a weighted average price of $10.00 per share, with individual trades executed between $10.00 and $10.01. The sales were made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a set schedule. After these transactions, the reporting person beneficially owns 8,666 shares of Verastem common stock directly.
Verastem, Inc. (VSTM) reported insider stock sales by its President and CEO, who is also a director. The reporting person sold 2,000 shares of common stock on each of 11/21/2025, 11/24/2025, and 11/25/2025, all at a price of $10 per share. These transactions are marked with transaction code "S," indicating open market or private sales.
After these sales, the reporting person beneficially owned 432,818 shares of Verastem common stock directly. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, which is intended to provide an affirmative defense for trading while limiting discretion over the timing and amount of trades.